Table 3. C-statistic for the base clinical model and incremental change with addition of novel biomarkers in the full study sample and intermediate risk population.

The base clinical model included age, sex, race/ethnicity, clinical center, ACR, eGFR, DM, CVD, systolic BP, BMI, ACE-I/ARB use, and education. Log-transformed biomarker results are expressed per log standard deviation

Model	Full study sample	Intermediate risk¶
Base clinical model	0.890	0.764
Base clinical model + log(KIM-1/Cr)	0.890	0.774
Base clinical model + log(KIM-1)	0.891	0.779
Base clinical model + log(NGAL/Cr)	0.890	0.766
Base clinical model + log(NGAL)	0.891	0.762
Base clinical model + log(NAG/Cr)	0.890	0.768
Base clinical model + log(NAG)	0.890	0.775
Base clinical model + L-FABP/Cr*	0.890	0.762
Base clinical model + L-FABP**	0.890	0.766

^*L-FABP/Cr was divided in to those with undetectable levels, those with absolute levels below the lower limit of detection, and then into tertiles of the normalized biomarker

^**LFABP was divided in to those with undetectable levels, those with absolute levels below the lower limit of detection, and then into tertiles of the raw biomarker

^¶Intermediate risk population had eGFR ≥60 ml/min/1.73m² and ACR ≥30 mg/g Cr; or eGFR 45–59 ml/min/1.73m² and ACR 0–300 mg/g Cr; or eGFR 30–44 ml/min/1.73m² and ACR <30 mg/g Cr